Strokes After TAVR. Ioannis Iakovou, MD, PhD. Interventional Cardiology Onassis Cardiac Surgery Center
|
|
- Quentin Cook
- 5 years ago
- Views:
Transcription
1 Strokes After TAVR Ioannis Iakovou, MD, PhD Interventional Cardiology Onassis Cardiac Surgery Center
2 Strokes After TAVR How common is stroke after TAVR Is it increasing? Is it more with TF vs TA? Is it different in SE or BE valves? How does this compare to surgery? Timing of stroke (procedural versus non procedural) Predictors of stroke after TAVR Prevention methods
3 Strokes After TAVR How common is stroke after TAVR Is it increasing? Is it more with TF vs TA? Is it different in SE or BE valves? How does this compare to surgery? Timing of stroke (procedural versus non procedural) Predictors of stroke after TAVR Prevention methods
4 Strokes After TAVR
5 Strokes After TAVR 30 Days -All Stroke from PARTNER Trials nonrandomized continued access (NRCA) registry cohort
6 Stroke : Feasibility Trials 25 multicenter registries and 33 single-center studies Athappan et al, JACC 2014
7 In hospital or 30 day stroke TA versus TF (Major Registries) Athappan et al, JACC 2014
8 In Hospital or 30 Day Stroke ES versus MC Major Registires Athappan et al, JACC 2014
9 Single Center (TF versus TA) Athappan et al, JACC 2014
10 30 day or in hospital stroke MC versus ES single center Athappan et al, JACC 2014
11 Strokes After TAVR How common is stroke after TAVR Is it increasing? Is it more with TF vs TA? Is it different in SE or BE valves? How does this compare to surgery? Timing of stroke (Procedural versus non procedural) Predictors of stroke after TAVR Prevention Methods
12 All Stroke : PARTNER A
13 CoreValveTrial : All Stroke 795 patients underwent randomization at 45 centers in the United States Adams, NEJM, 2014
14 High Risk Surgical AVR and Stroke A retrospective review was performed on 159 patients Thourani et al, Ann ThoracSurg2011;91:49 56
15 prospective cohort study of subjects 65 years of age who were undergoing AVR for calcific aortic stenosis. Subjects were evaluated by neurologists preoperatively and postoperatively and underwent postoperative magnetic resonance imaging. Messe, Circulation, 2014
16 Strokes After TAVR How common is stroke after TAVR Is it increasing? Is it more with TF vs TA? Is it different in SE or BE valves? How does this compare to surgery? Timing of stroke (Procedural versus non procedural) Predictors of stroke after TAVR Prevention Methods
17 Stroke Timing within 1 year
18 Strokes After TAVR How common is stroke after TAVR Is it increasing? Is it more with TF vs TA? Is it different in SE or BE valves? How does this compare to surgery? Timing of stroke (Procedural versus non procedural) Predictors of stroke after TAVR Prevention Methods
19 Risk factors for Neurologic Events Samir Kapadia TCT 2014
20 TAVR and Stroke : Registry Data Samir Kapadia TCT 2014
21 Predictors of Stroke, Neuro events or MRI findings Samir Kapadia TCT 2014
22 Impact of Post-Dilatation Nombela-Franco et al, J Am Coll Cardiol Intv 2012;5:
23 Canadian Experience 1061 Patients 5 centers 679 (65%) Balloon expandable 361 (34%) Self expandable Analysis of events depending on timing of stroke Nombela-Franco et al, J Am Coll Cardiol Intv 2012;5:
24 Predictors of Early (30-Day) CVEs Nombela-Franco et al, J Am Coll Cardiol Intv 2012;5:
25 Predictors of Late CVEs (>30-day) Nombela-Franco et al, J Am Coll Cardiol Intv 2012;5:
26 Timing of NOAF after TAVR 138 consecutive patients with no prior history of atrial fibrillation (AF) underwent TAVI with a balloon-expandable valve NOAF occurred in 44 patients (31.9%) at a median time of 48 h Amat-Santoset al, JACC2012;59:178 88
27 New Onset AF after TAVR and Stroke NOAF was associated with a higher rate of stroke/systemic embolism, but not a higher mortality, at 30 days and at 1-year follow-up. Amat-Santoset al, JACC2012;59:178 88
28 Strokes After TAVR How common is stroke after TAVR Is it increasing? Is it more with TF vs TA? Is it different in SE or BE valves? How does this compare to surgery? Timing of stroke (Procedural versus non procedural) Predictors of stroke after TAVR Prevention Methods
29 Stroke Prevention Measures
30 Emboli Protection Devices
31 Histopathology Claret Debris Capture Van Mieghem et al, Circulation 2013;127:
32 US IDE Sentinel Study Summary Cerebral Protection in Transcatheter Aortic Valve Replacement The SENTINEL Study Study Objective Assess the safety and efficacy of the Claret Medical SentinelCerebral Protection System for embolic protection during Transcatheter Aortic Valve Replacement (TAVR) compared to TAVR standard of care (without embolic protection) Study Population Subjects with severe symptomatic calcified native aortic valve stenosis who meet the commercially approved indications for TAVR with the Edwards SAPIEN THV or XT (if approved) Number of Centers Up to 15 clinical study centers
33 Implication Stroke prevention will help to move to lower risk patients It may be an advantage rather than disadvantage for TAVR compared to SAVR (similar to PCI compared to CABG)
34 Thank you!
Strokes After TAVR. Incidence (past and present) Multi-factorial Origin
Strokes After TAVR Incidence (past and present) Multi-factorial Origin Samir Kapadia, MD Professor of Medicine Director, Cardiac Catheterization Laboratory Cleveland Clinic All faculty disclosures are
More informationIs Stroke Frequency Declining?
Is Stroke Frequency Declining? Etiologic Factors Clinical, Anatomic, Technique-related, and Device-specific Samir Kapadia, MD Professor of Medicine Section head, Interventional Cardiology Director, Cardiac
More informationStrokes After TAVR Reasons for Declining Frequency
Strokes After TAVR Reasons for Declining Frequency Samir Kapadia, MD Professor of Medicine Director, Cardiac Catheterization Laboratory Cleveland Clinic Disclosure NONE Second Generation Valves Newer
More informationStrokes After TAVR Multi-factorial Origin, Incidence (past and present), and Management Considerations (present and future)
Strokes After TAVR Multi-factorial Origin, Incidence (past and present), and Management Considerations (present and future) Samir Kapadia, MD Professor of Medicine Director, Cardiac Catheterization Laboratory
More informationRole of Embolic Protection during TAVR
Role of Embolic Protection during TAVR Samir Kapadia, MD Professor of Medicine Section head, Interventional Cardiology Director, Cardiac Catheterization Laboratories Disclosure Co PI for Sentinel Trial
More informationIs Cerebral Embolic Protection Needed for TAVR?
Is Cerebral Embolic Protection Needed for TAVR? The Evidence: Observations From DEFLECT 3, CLEAN-TAVI, and the SENTINEL Clinical Trials Samir Kapadia, MD Professor of Medicine Section head, Interventional
More informationNeuroprotection During TAVR
Neuroprotection During TAVR Samir Kapadia, MD Professor of Medicine Section head, Interventional Cardiology Director, Cardiac Catheterization Laboratories Cleveland Clinic Cleveland Clinic Disclosure Co
More informationThe Case for and Against Cerebral Embolic Protection During TAVR. Susheel Kodali, MD
The Case for and Against Cerebral Embolic Protection During TAVR Susheel Kodali, MD Director, Structural Heart & Valve Center Columbia University Medical Center New York Presbyterian Hospital Disclosure
More informationPost-TAVI Cerebral Embolisms and Potential Protection Means
Post-TAVI Cerebral Embolisms and Potential Protection Means Josep Rodés-Cabau, MD Quebec Heart & Lung Institute, Laval University Quebec City, Quebec, Canada EBR Marseille, May 2012 Conflict of Interest
More informationThe Sentinel Dual Filter Device Design Features & EU Clinical Trial Results
The Sentinel Dual Filter Device Design Features & EU Clinical Trial Results Nicolas M. Van Mieghem, MD, PhD, FESC Director of Interventional Cardiology Thoraxcenter, Erasmus MC Rotterdam Disclosure Statement
More informationTranscatheter Aortic Valve Replacement
Transcatheter Aortic Valve Replacement Jesse Jorgensen, MD Medical Director, Cardiac Catheterization Laboratory Greenville Health System Greenville, South Carolina, USA January 30, 2016 Aortic Stenosis
More informationEmbolic Protection Devices for Transcatheter Aortic Valve Replacement
Embolic Protection Devices for Transcatheter Aortic Valve Replacement James M. McCabe, MD Medical Director, Cardiac Cath Lab University of Washington Seattle, WA Disclosures Proctoring and honoraria for
More informationThe Role of TAVI in high-risk and normal-risk Patients
The Role of TAVI in high-risk and normal-risk Patients Joachim Schofer Hamburg University Cardiovascular Center and Department for percutaneous treatment of structural heart disease Albertinen Heart Center
More informationTAVR in Intermediate Risk Populations /Optimizing Systems for TAVR
TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR Saibal Kar, MD, FACC, FAHA, FSCAI Professor of Medicine Director of Interventional Cardiac Research Smidt Heart Institute, Cedars-Sinai
More informationParavalvular Regurgitation is a Risk Factor Following TAVI
Paravalvular Regurgitation is a Risk Factor Following TAVI Philippe Pibarot, DVM, PhD, FACC, FESC, FASE Canada Research Chair in Valvular Heart Disease INSTITUT UNIVERSITAIRE DE CARDIOLOGIE ET DE PNEUMOLOGIE
More informationDO WE NEED TO DO BETTER?
A critical review of the neurological effects of invasive cardiac procedures: DO WE NEED TO DO BETTER? Pieter Stella, MD, PhD University Medical Center Utrecht, The Netherlands Disclosure - Member Advisory
More informationAortic Stenosis: Background
Transcatheter Aortic Valve Replacement in Low Surgical Risk Patients Barry George, MD The Ohio State University Structural Heart Disease Course May 19 th, 2017 Aortic Stenosis: Background Severe Symptomatic
More informationHow to Prevent Thromboembolic Complications in TAVI
How to Prevent Thromboembolic Complications in TAVI PETER WENAWESER, MD Swiss Cardiovascular Centre, University Hospital, Bern, Switzerland Potential Conflicts of Interest Proctoring and lecture fees from
More informationTAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central
TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central Michigan University 1 Disclosure Chiesi Pharma- Consultant
More informationMild paravalvular regurgitation is not an independent predictor of mortality following TAVI
Mild paravalvular regurgitation is not an independent predictor of mortality following TAVI Philippe Pibarot, DVM, PhD, FACC, FAHA, FASE Canada Research Chair in Valvular Heart Diseases INSTITUT UNIVERSITAIRE
More informationTAVR in patients with. End-Stage CKD or in Renal Replacement Therapy:
TAVR in patients with End-Stage CKD or in Renal Replacement Therapy: Special Considerations and Prevention of early Valve Failure Antonios Chalapas, MD, PhD, FESC THV & Hygeia Hospital Heart Team Athens,
More informationTAVR: Review of the Robust Data from Randomized Trials
TAVR: Review of the Robust Data from Randomized Trials Nicholas J. Ruggiero II, MD,FACP, FACC, FSCAI, FSVM, FCPP Director, Structural Heart Disease and Non-Coronary Interventions Director, Jefferson Heart
More informationAntithrombotic. DAPT or OAC?
Antithrombotic treatment after TAVI: DAPT or OAC? Striking the right balance. Pascal Vranckx MD, PhD. Hartcentrum Hasselt, Belgium. Disclosure of Interest Pascal Vranckx has the following potential conflicts
More informationIndication, Timing, Assessment and Update on TAVI
Indication, Timing, Assessment and Update on TAVI Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Starr- Edwards Mechanical
More informatione Corrado Tamburino, MD, PhD
Transcatheter Aortic Valve Implantation Stroke: etiology ogy and prevention e Corrado Tamburino, MD, PhD Full Professor of Cardiology, Director of Postgraduate School of Cardiology Chief Cardiovascular
More informationTranscatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40
Transcatheter Aortic Valve Implantation SSVQ November 23, 2012 Centre Mont-Royal 15:40 Nicolo Piazza MD, PhD, FRCPC, FESC, FACC McGill University Health Center German Heart Center Munich 1 First-in-Human
More informationIgor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School
Aortic Stenosis: Current State of Percutaneous Therapies, Emerging Technologies and Future Directions Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of
More informationRANDOMISED TRIALS TAVI WITH SAVR STEPHAN WINDECKER AORTIC VALVE DISEASE COMPARING
AORTIC VALVE DISEASE RANDOMISED TRIALS COMPARING TAVI WITH SAVR STEPHAN WINDECKER DEPARTMENT OF CARDIOLOGY SWISS CARDIOVASCULAR CENTER AND CLINICAL TRIALS UNIT BERN BERN UNIVERSITY HOSPITAL, SWITZERLAND
More informationIncorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)
Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI) Larry S. Dean, MD, MSCAI Past President SCAI Professor of Medicine and Surgery University of Washington School of Medicine
More information2/15/2018 DISCLOSURES OBJECTIVES. Consultant for BioSense Webster, a J&J Co. Aortic stenosis background. Short history of TAVR
TRANSCATHETER AORTIC VALVE REPLACEMENT IN 2018: IS IT NOW THE STANDARD OF CARE? 22 ND ANNUAL COASTAL CARDIAC & VASCULAR CONFERENCE FEBRUARY 17, 2018 R. David Anderson, MD, MS, FACC, FSCAI Professor of
More informationProtection Devices for Stroke Prevention Do the Data support their Routine Use?
ACC 2015 San Diego, March 14-16 nd, 2015 Protection Devices for Stroke Prevention Do the Data support their Routine Use? Eberhard Grube MD, FACC University Hospital, Dept of Medicine II, Bonn, Germany
More informationCerebral Protection In Transcatheter Aortic Valve Replacement The SENTINEL Study. Susheel Kodali, MD Columbia University Medical Center
Cerebral Protection In Transcatheter Aortic Valve Replacement The SENTINEL Study Susheel Kodali, MD Columbia University Medical Center Disclosure Statement of Financial Interest Susheel Kodali, MD Within
More informationRole of Embolic Protection Devices in TAVR: Are They Needed? Waste of Time and Money?
Role of Embolic Protection Devices in TAVR: Are They Needed? Waste of Time and Money? Gian Paolo Ussia Campus Bio-medico University, Rome Italy g.ussia@unicampus.it REQUIRED Gian Paolo Ussia I have no
More informationNeal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute
Neal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute Despite a 33 fold growth in the first five years, there is still tremendous variability among penetration in different countries
More informationAn Update on the Edwards TAVR Results. Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St.
An Update on the Edwards TAVR Results Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St. Luke s Hospital Disclosures On the speaker s bureau for Endologix, TriVascular,
More informationA new option for the Diagnosis and Management of Valvular Heart Disease. Oregon Comprehensive Valve Center
A new option for the Diagnosis and Management of Valvular Heart Disease Oregon Comprehensive Valve Center I have no disclosures Oregon Comprehensive Valve Center Weekly multidisciplinary case conferences
More informationTAVR for low-risk patients in 2017: not so fast.
TAVR for low-risk patients in 2017: not so fast. Enrico Ferrari, MD, FETCS Cardiac Surgery Department Cardiocentro Ticino Foundation Lugano, Switzerland Conflicts of Interest Consultant and proctor for
More informationCIPG Transcatheter Aortic Valve Replacement- When Is Less, More?
CIPG 2013 Transcatheter Aortic Valve Replacement- When Is Less, More? James D. Rossen, M.D. Professor of Medicine and Neurosurgery Director, Cardiac Catheterization Laboratory and Interventional Cardiology
More informationTAVI limitations for low risk patients
TAVI limitations for low risk patients Dr. T. Modine / P. Lancellotti MD, PhD, MBA CHRU de Lille, France Potential conflicts of interest Speaker's name: Thomas Modine I have the following potential conflicts
More informationCoreValve High Risk Study - Neu
CoreValve High Risk Study - Neu Adams DH et al. NEJM 2014 CoreValve US Pivotal Trial Reardon MJ et al. ACC 2015 Stroke incidence and mortality after TAVI Meta-analysis of 10,037 published patients Stroke
More informationTAVR IN INTERMEDIATE-RISK PATIENTS
TAVR IN INTERMEDIATE-RISK PATIENTS K. Lampropoulos MD, PhD, FESC, MEAPCI Interventional Cardiologist Evangelismos General Hospital The Burden of Valve Disease Prevalence Survival NATURAL HISTORY OF AS
More informationSentinel Dual Filter Device: Technology Overview and Status of the CLEAN-TAVI Randomized Trial. Martin B. Leon, MD
8 mins Sentinel Dual Filter Device: Technology Overview and Status of the CLEAN-TAVI Randomized Trial Martin B. Leon, MD Columbia University Medical Center Cardiovascular Research Foundation New York City
More informationIs TAVI ready for prime time in: - Intermediate risk patients? - Low risk patients?
Is TAVI ready for prime time in: - Intermediate risk patients? - Low risk patients? Didier TCHETCHE, MD. Clinique PASTEUR, Toulouse, France, Conflicts of interest: -Consultant for Edwards LifeSciences
More informationTAVI After PARTNER-2 : The Hamilton Approach
TAVI After PARTNER-2 : The Hamilton Approach James L. Velianou MD FRCPC Interventional Cardiology Hamilton General Hospital St Catharines General Hospital Associate Professor of Medicine McMaster University
More informationTranscatheter Valve Replacement: Current State in 2017
Transcatheter Valve Replacement: Current State in 2017 Marc A. Sintek MD Assistant Professor of Medicine Interventional Cardiology Cardiovascular Division Washington University in St. Louis Missouri ACP
More informationAppropriate Use of TAVR - now and in the future. A Surgeon s Perspective. Neil Moat Royal Brompton Hospital, London, UK
Appropriate Use of TAVR - now and in the future A Surgeon s Perspective Neil Moat Royal Brompton Hospital, London, UK Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner
More informationTrans Aortic Valve Replacement Update: 2016 & Beyond
Trans Aortic Valve Replacement Update: 2016 & Beyond Rajiv Jauhar, MD, FACC, FSCAI Chief of Cardiology Director of Cardiac Cath Labs Northshore University Hospital, Manhasset 1 DISCLOSURE POLICY Northwell
More informationFive-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis: The PARTNER Trial
Five-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis: The PARTNER Trial Samir R. Kapadia, MD On behalf of The PARTNER Trial Investigators
More informationLe TAVI pour tout le monde?
Le TAVI pour tout le monde? Thierry Lefèvre Institut Cardiovasculaire Paris Sud, Massy Disclosure Statement of Financial Interest I currently have, or have had over the last two years, an affiliation or
More informationThe PARTNER II Trial: Placement of AoRTic TraNscathetER Valves Trial II
Department of Medicine Director, Transcatheter Aortic Valve Program June 2013 [First Name] [Last Name], [Suffix] [Hospital or Practice Name] [Address] [City], [State] [Zip] Dear Dr. [Last name], We are
More informationTAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy
TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy Alan Zajarias, MD FACC Structural Interventional Fellowship Director Associate Professor Medicine Cardiovascular Division
More informationSAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes
SAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes Howard C. Herrmann, MD on behalf of The PARTNER II Trial
More informationTranscatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients:
Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients: 1-Year Results from the SURTAVI Clinical Trial Nicolas M. Van
More informationAndrzej Ochala, MD Medical University of Silesia, Katowice, Poland
Andrzej Ochala, MD Medical University of Silesia, Katowice, Poland Bicuspid aortic valve o Most common congenital heart disease in adults (1% - 2%) o AS is the most common complication of BAV o Patophysiology
More informationAortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV?
Aortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV? Samin K Sharma, MD, FACC, FSCAI Director Clinical & Interventional
More informationTrans Catheter Aortic Valve Replacement
Trans Catheter Aortic Valve Replacement Satish K Surabhi, MD,FACC,FSCAI Medical Director, Cardiac Cath Labs AnMed Health Heart and Vascular Care No financial conflict of interest related to this talk Will
More informationTranscatheter Aortic-Valve Implantation for Aortic Stenosis
Transcatheter Aortic-Valve Implantation for Aortic Stenosis Policy Number: 7.01.132 Last Review: 6/2018 Origination: 2/2012 Next Review: 2/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC)
More informationValve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal
Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal I have nothing to disclose. Wide Spectrum Stable vs Decompensated NYHA II IV? Ejection
More informationTAVR y Enfermedad Coronaria. Mauricio G. Cohen, MD, FACC, FSCAI Director, Cardiac Catheterization Lab Associate Professor of Medicine
TAVR y Enfermedad Coronaria Mauricio G. Cohen, MD, FACC, FSCAI Director, Cardiac Catheterization Lab Associate Professor of Medicine CAD and AS Similar Pathological Processes CAD in TAVR Patients (n=390)
More informationTranscatheter Aortic-Valve Implantation for Aortic Stenosis
Transcatheter Aortic-Valve Implantation for Aortic Stenosis Policy Number: 7.01.132 Last Review: 2/2019 Origination: 2/2012 Next Review: 2/2020 Policy Blue Cross and Blue Shield of Kansas City (Blue KC)
More informationCerebral Embolic Protection In Patients Undergoing Surgical Aortic Valve Replacement (SAVR)
Cerebral Embolic Protection In Patients Undergoing Surgical Aortic Valve Replacement (SAVR) Michael Mack, MD, Michael Acker, MD, Steve Messe, MD For the Cardiothoracic Surgical Trials Network (CTSN) American
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Transcatheter Aortic Valve Implantation for Aortic Stenosis Page 1 of 37 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Transcatheter Aortic Valve Implantation
More informationAortic Stenosis: Open vs TAVR vs Nothing
Aortic Stenosis: Open vs TAVR vs Nothing Wilson Y. Szeto, MD Associate Professor of Surgery Surgical Director, Transcatheter Cardio-Aortic Therapies Associate Director, Thoracic Aortic Surgery Division
More informationDavid Dexter MD FACS Sentara Vascular Specialists Assistant Professor of Surgery EVMS. Peripheral Complications of TAVR
David Dexter MD FACS Sentara Vascular Specialists Assistant Professor of Surgery EVMS Peripheral Complications of TAVR TAVR Complications Reported Complications Rates range from 8% to 15% Predictors of
More informationSelection of aortic valve replacement versus transcatheter aortic valve replacement in high-risk patients: a Markov model
Selection of aortic valve replacement versus transcatheter aortic valve replacement in high-risk patients: a Markov model Hemal Gada, MD, MBA and Thomas H Marwick, MD, PhD Department of Cardiovascular
More informationThe SAPIEN 3 TAVI Advantage
Edwards SAPIEN 3 Valve The SAPIEN 3 TAVI Advantage... The SAPIEN 3 TAVI Advantage The clear choice for your patients and your TAVI program Advanced valve and system designed to simplify procedures Consistent
More informationVARC-2 and MVRC definitions Ioannis Iakovou, MD, PhD
VARC-2 and MVRC definitions Ioannis Iakovou, MD, PhD Interventional Cardiology Onassis Cardiac Surgery Center Athens, Greece Aims of Valve Academic Research Consortium (VARC) (i) selecting appropriate
More informationANTICOAGULATION IN SPECIFIC POPULATIONS: BIOLOGICAL HEART VALVES, TAVI
ESC Cardiovascular Round Table 27 March 2017, Amsterdam ANTICOAGULATION IN SPECIFIC POPULATIONS: BIOLOGICAL HEART VALVES, TAVI Stephan Windecker Department of Cardiology Swiss Cardiovascular Center Bern
More informationSubclinical Thrombosis of Bioprosthetic Aortic Valves: Is It Clinically Relevant? Tarun Chakravarty, MD
Subclinical Thrombosis of Bioprosthetic Aortic Valves: Is It Clinically Relevant? Tarun Chakravarty, MD Interventional Cardiology Cedars-Sinai Heart Institute Disclosures Consultant and proctor for Edwards
More informationTAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con
TAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con Dimitrios C. Angouras, MD, FETCS Associate Professor of Cardiac Surgery National and Kapodistrian University of Athens,
More informationSevere Aortic Valve Disease: TAVR in Four Ages and Four Etiologies Age 25 y/o Congenital, 50 y/o Bicuspid, 75 y/o Rheumatic, 100 y/o Degenerative
Severe Aortic Valve Disease: TAVR in Four Ages and Four Etiologies Age 25 y/o Congenital, 50 y/o Bicuspid, 75 y/o Rheumatic, 100 y/o Degenerative Samin K. Sharma, MD, FACC, FSCAI Director Clinical & Interventional
More informationPredictors, incidence and outcomes of patients undergoing transcatheter aortic valve implantation complicated by stroke
Predictors, incidence and outcomes of patients undergoing transcatheter aortic valve implantation complicated by stroke From the CENTER-Collaboration Wieneke Vlastra, MD Heart Center, Amsterdam UMC, University
More informationComplicanze durante TAVI. Brambilla Nedy IRCCS Policlinico San Donato
Complicanze durante TAVI Brambilla Nedy IRCCS Policlinico San Donato 0 2 4 6 9 11 14 16 22 26 31 33 37 43 52 61 69 78 87 93 106 113 121 151 171 186 201 225 267 283 294 311 349 502 515 709 1007 Number of
More informationPARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients
O P E N A C C E S S Department of Cardiology, Aswan Heart Centre *Email: ahmed.elguindy@aswanheartcentre.com Lessons from the trials PARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients Ahmed ElGuindy*
More informationValvular Intervention
Valvular Intervention Outline Introduction Aortic Stenosis Mitral Regurgitation Conclusion Calcific Aortic Stenosis Deformed Eccentric Calcified Nodular Rigid HOSTILE TARGET difficult to displace prone
More informationTranscatheter aortic valve replacement is considered investigational for all other indications.
Medical Policy Original Policy Date: March 30, 2012 Effective Date: July 1, 2018 Section: 7.0 Surgery Page: Page 1 of 33 Policy Statement Transcatheter aortic valve replacement with an U.S. Food and Drug
More informationExtension to medium and low risk patients? Friedrich Eckstein University Hospital Basel
TAVI CON Extension to medium and low risk patients? Friedrich Eckstein University Hospital Basel Extension to medium and low risk patients? In octogenerians already reality in most of the swiss clinics!?
More informationAortic stenosis (AS) remains the most common
Sapien Valve: Past, Present, and Future A look at how the Sapien family of valves continues to evolve to treat a range of patients seeking transcatheter aortic valve replacement. BY RAVINDER SINGH RAO,
More informationWhy Cerebral Protection after TAVR Will Become the Standard of Care
Vancouver, June 5 th, 2014 Why Cerebral Protection after TAVR Will Become the Standard of Care Eberhard Grube MD, FACC, FSCAI University Hospital, Dept of Medicine II, Bonn, Germany Stanford University,
More informationPercutaneous Management of Severe AS in Octagenarians. Phillip Matsis FRACP FCSANZ Interventional Cardiologist Wakefield Heart Centre Wellington
Percutaneous Management of Severe AS in Octagenarians Phillip Matsis FRACP FCSANZ Interventional Cardiologist Wakefield Heart Centre Wellington May 2017 Outline Aetiology of AS Natural History of AS Assessment
More informationTAVI: Nouveaux Horizons
TAVI: Nouveaux Horizons EUAPI580i 432HQ14NP02353 Institut de Cardiologie de la Pitié-Salpêtrière jean-philippe.collet@psl.aphp.fr www.action-coeur.org Objectifs Les recommandations Le TAVI en chiffre La
More informationTranscatheter heart valve thrombosis
Transcatheter heart valve thrombosis Jeroen J Bax Dept Cardiology Leiden, The Netherlands New York, 2017 The department of Cardiology of the Leiden University Medical center received research grants from
More informationBuilding the Evidence for CEP in TAVR: A Critical Review of the Clinical Trial Data
Building the Evidence for CEP in TAVR: A Critical Review of the Clinical Trial Data Jeffrey W. Moses, MD Professor of Medicine Director, Interventional Cardiac Therapeutics Columbia University Medical
More informationTAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre
TAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre Disclosure St. Jude Medical: Consultant and Proctor Edwards Lifesciences: Proctor Medtronic: Research
More informationL evoluzione nel management della valvulopatia aortica
L evoluzione nel management della valvulopatia aortica Giuseppe Tarantini, MD, PhD, FESC Director of Interventional Cardiology University of Padua GISE president TAVI: BIG BANG 2002 TAVI - EVOLUTIONs Commitment
More informationMinimalist Transcatheter Aortic Valve Replacement (MA-TAVR)
Minimalist Transcatheter Aortic Valve Replacement (MA-TAVR) Jensen HA, Condado JF, Devireddy C, Binongo JN, Leshnower BG, Babaliaros V, Sarin EL, Lerakis S, Guyton RA, Stewart JP, Syed AQ, Mavromatis K,
More informationValve Replacement without a Scalpel Transcatheter Aortic Valve Replacement (TAVR) Charles T. Klodell, M.D.
Valve Replacement without a Scalpel Transcatheter Aortic Valve Replacement (TAVR) Charles T. Klodell, M.D. Professor, Thoracic and Cardiovascular Surgery University of Florida klodell@surgery.ufl.edu Disclosures
More informationStrokes After TAVR: Perspectives from the US CoreValve Trials
Strokes After TAVR: Perspectives from the US CoreValve Trials Jeffrey J. Popma, MD Professor of Medicine Harvard Medical School Director, Interventional Cardiology Clinical Services Beth Israel Deaconess
More informationAortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC
Aortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC No Financial Disclosures Aortic Stenosis AS is an insidious disease with a long latency period followed by
More informationAccepted Manuscript. Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement: A Disconnect Between Logic and Data?
Accepted Manuscript Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement: A Disconnect Between Logic and Data? Azeem Latib, MD, Matteo Pagnesi, MD PII: S0735-1097(16)36808-5 DOI: 10.1016/j.jacc.2016.10.036
More information1-YEAR OUTCOMES FROM JOHN WEBB, MD
1-YEAR OUTCOMES FROM JOHN WEBB, MD ON BEHALF OF THE SAPIEN 3 INVESTIGATORS UNIVERSITY OF BRITISH COLUMBIA VANCOUVER, CANADA Potential conflicts of interest Speaker's name: John Webb I have the following
More informationEvolving and Expanding Indications for TAVR
Evolving and Expanding Indications for TAVR Wilson Y. Szeto, MD Associate Professor of Surgery Surgical Director, Transcatheter Cardio-Aortic Therapies Associate Director, Thoracic Aortic Surgery Division
More informationIs TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients
Is TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients Saibal Kar, MD, FACC, FAHA, FSCAI Director of Interventional Cardiac Research Cedars Sinai Heart Institute, Los Angeles, CA Potential
More informationState of the Art and Future perspective
State of the Art and Future perspective Giuseppe Tarantini, MD, PhD, FESC Associate professor University of Padua Director Interventional Cardiology Dpt of Cardiac Thoracic and Vascular Sciences, Padua
More informationThe Heart Team and the minimalist approach to TAVR today Is there a conflict? G T Stavridis MD FETCS Onassis Cardiac Surgery Ctr.
The Heart Team and the minimalist approach to TAVR today Is there a conflict? G T Stavridis MD FETCS Onassis Cardiac Surgery Ctr. DISCLOSURES Conflicts of interest: none Minimalist approach (MA) Cath lab
More informationAppropriate Patient Selection or Healthcare Rationing? Lessons from Surgical Aortic Valve Replacement in The PARTNER I Trial Wilson Y.
Appropriate Patient Selection or Healthcare Rationing? Lessons from Surgical Aortic Valve Replacement in The PARTNER I Trial Wilson Y. Szeto, MD on behalf of The PARTNER Trial Investigators and The PARTNER
More informationThe Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health. Adam J. Saltzman, MD Cardiovascular Care Center
The Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health Adam J. Saltzman, MD Cardiovascular Care Center Southcoast Health Disclosures Edwards Lifesciences: speaking honorarium Outline
More informationTAVI Technology and Procedural Changes
TCT AP 2013 Seoul, South Korea April, 2013 TAVI Technology and Procedural Changes Eberhard Grube MD, FACC, FSCAI University Hospital, Dept of Medicine II, Bonn, Germany Hospital Alemão Oswaldo Cruz, São
More informationWhen Should We Consider TAVI. (Surgeon s Viewpoint)? Pyowon Park Samsung Medical Center Seoul, Korea
When Should We Consider TAVI Procedure in Korea (Surgeon s Viewpoint)? Pyowon Park Samsung Medical Center Seoul, Korea Aortic Stenosis in Korea Rapidly increasing valve disease in Korea Still low incidence
More informationTranscatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data
Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data Echo Florida 2013 Jonathan J. Passeri, M.D. Co-Director, Heart Valve Program Director,
More information